News

Nonprofit in Philadelphia's Kensington neighborhood working to prevent HIV infections
Prevention Point Philadelphia, a nonprofit, has been on the front lines of harm reduction for more than 30 years.
Nigerian company to make HIV, malaria test kits after US funding cut
Nigerian manufacturer Codix Bio Ltd plans to make millions of HIV and Malaria test kits at its new plant outside Lagos for ...
FDA approves new twice-yearly HIV shot. What to know
The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...
FDA approves first twice-yearly injection that prevents HIV infection
The U.S. Food and Drug Administration (FDA) approved a new, twice-yearly shot — the first and only of its kind — to prevent ...
FDA approves twice-yearly shot to prevent HIV
ABC News contributor Dr. Alok Patel and Ian Haddock, founder of the Normal Anomaly Initiative, discuss the FDA’s decision to ...
FDA approves twice-a-year injection for HIV prevention
A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug ...
HIV prevention drug lenacapavir approved by FDA as twice-yearly injection
Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...
FDA approves long-lasting HIV-prevention drug
The Food and Drug Administration has approved a new drug that could prevent HIV infections with just two shots every year and ...
The World's Only Twice-A-Year Shot to Prevent HIV Could Stop Transmission — if People Can Get It
WASHINGTON (AP) — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated ...
US FDA approves Gilead's twice-yearly injection for HIV prevention
The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences lenacapavir, a twice-yearly injection, for ...
The FDA Approves Powerful HIV Prevention Drug
But the Trump administration’s cuts to HIV programs in the U.S. and abroad could undermine the drug’s rollout.